MYOS - MYOS RENS Technology Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7000
+0.0300 (+1.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6700
Open1.7500
Bid1.5200 x 4000
Ask1.7400 x 3200
Day's Range1.6500 - 1.7500
52 Week Range1.0400 - 2.5000
Volume26,240
Avg. Volume41,845
Market Cap15.307M
Beta (3Y Monthly)0.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire9 days ago

    MYOS RENS' Fortetropin® Shown to Increase the Rate of Muscle Protein Synthesis in Older Adults in Clinical Study Carried out at University of California, Berkeley

    Significant Potential for Reducing Age-Related Muscle Loss Conference Call Wednesday, June 19th at 11:00 a.m. ET CEDAR KNOLLS, N.J. , June 18, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" ...

  • PR Newswire29 days ago

    MYOS RENS Technology Announces Endorsement Partnership for Yolked® with Carli Lloyd, Two-Time Olympic Gold Medalist, FIFA Women's World Cup Champion, and Captain of the United States Women's National Soccer Team

    CEDAR KNOLLS, N.J., May 29, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced their latest endorsement partnership with Carli Lloyd, an American superstar soccer player and two-time Olympic gold medalist, FIFA Women's World Cup champion,  two-time FIFA Women's Player of the Year and three-time Olympian. As part of the endorsement partnership, Lloyd will serve as an endorser of Yolked®, our NSF Certified for Sport® branded sports nutrition product, to the millions of soccer fans across the world and appear in multiple marketing campaigns to promote Yolked, which is scientifically proven to help build more lean muscle and decrease muscle loss.

  • PR Newswirelast month

    MYOS RENS Technology to Present at the 9th Annual LD Micro Invitational in Los Angeles, CA

    Company Presentation on Tuesday, June 4 at 3:40pm PT to Highlight its Core Nutritional Products CEDAR KNOLLS, N.J. , May 21, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") ...

  • PR Newswire2 months ago

    MYOS RENS Technology Reports 161% Increase in Revenues, 238% Increase in Gross Profit in First Quarter 2019

    Conference Call to be Held Tomorrow at 11am ET CEDAR KNOLLS, N.J. , May 8, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition ...

  • PR Newswire2 months ago

    MYOS RENS Technology Announces the Date for the Release of First Quarter 2019 Results, Conference Call and Webcast

    CEDAR KNOLLS, N.J., May 1, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it will provide financial results for the first quarter 2019 on Wednesday, May 8, 2019 after the market closes. The Company will host a conference call on Thursday, May 9, 2019 at 11 AM ET, at which time MYOS' Chief Executive Officer Joseph Mannello will provide commentary on earnings results for the first quarter and provide an update on the business.

  • PR Newswire3 months ago

    MYOS RENS Technology Signs Distribution Agreement with National Sales Associates, LLC

    CEDAR KNOLLS, N.J., April 4, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it has signed a national brokerage agreement with National Sales Associates ("NSA"), which will allow MYOS to sell its NSF "Certified for Sport®" sports nutrition brand, Yolked®, along with our pet product MYOS Canine Muscle Formula® ("MYOS Canine") throughout its national sales network of eight regional offices with over 160 associates.

  • PR Newswire3 months ago

    MYOS RENS Technology Reports Fourth Quarter and Fiscal 2018 Results

    Conference Call to be Held Thursday, March 28, 2019 , at 11am ET CEDAR KNOLLS, N.J. , March 28, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), ...

  • PR Newswire3 months ago

    MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Fiscal Year 2018 Results, Conference Call and Webcast

    CEDAR KNOLLS, N.J., March 26, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it will provide financial results for the fourth quarter and fiscal year 2018 on Wednesday, March 27, 2019 after the market closes. The Company will host a conference call on Thursday, March 28, 2019 at 11 AM ET, at which time MYOS' Chief Executive Officer Joseph Mannello will provide commentary on earnings results for the fourth quarter and year end and provide an update on the business.

  • PR Newswire4 months ago

    MYOS RENS Technology Announces Initiation of a Study at Kansas State University to Evaluate the Impact of Fortetropin® on Quality of Life and Activity in Geriatric Dogs

    CEDAR KNOLLS, N.J., Feb. 27, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced that it has signed an agreement with Kansas State University College of Veterinary Medicine to evaluate the impact of Fortetropin on quality of life and activity in geriatric dogs.  The study will be performed under the supervision of Kenneth R. Harkin, DVM, DACVIM (SAIM), Professor and Section Head, Small Animal Internal Medicine.

  • GlobeNewswire4 months ago

    Report: Exploring Fundamental Drivers Behind Crocs, Portola Pharmaceuticals, ANSYS, Alpha and Omega Semiconductor, PetMed Express, and MYOS RENS Technology — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • PR Newswire5 months ago

    MYOS RENS Technology Announces First Endorsement Deal for Yolked® with NBA Superstar Aaron Gordon

    CEDAR KNOLLS, N.J., Feb. 7, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced an endorsement partnership with NBA superstar Aaron Gordon of the Orlando Magic.

  • PR Newswire5 months ago

    MYOS CEO Joseph Mannello Issues Letter to Shareholders Following Presentation at North American Veterinary Community (NAVC) Conference/VMX

    CEDAR KNOLLS, N.J., Jan. 23, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, has issued the following letter to shareholders from CEO Joseph Mannello. VMX is one of the largest conferences in the world dedicated to Veterinary Medicine with over 17,000 delegates and over 700 exhibiting companies in attendance.  I attended VMX and spoke  directly with veterinarians at the MYOS booth, where there was tremendous activity and interest.  Many of these veterinarians said that they believe that our new Fortetropin®-based product, MYOS Canine Muscle Formula® will be a "game-changer" as there is "finally" a product that is effective in the canine market for muscle health.   We believe that the study results will have truly transformative potential for the Company.  Below is a brief discussion regarding the study and its potential impact on our business.

  • PR Newswire5 months ago

    MYOS RENS Technology Announces Study Results Demonstrating Fortetropin®, the Active Ingredient in Myos Canine Muscle Formula, Prevents Muscle Loss in Canines After Surgery and Enhances Recovery

    Positive Results Obtained from Kansas State University Study Company to Host Update Conference Call Today at 11:00 a.m. ET to Discuss Results CEDAR KNOLLS, N.J. , Jan. 15, 2019 /PRNewswire/ -- MYOS RENS ...

  • PR Newswire6 months ago

    MYOS RENS Technology Announces Upcoming Presentation of Results from a Kansas State University Study Evaluating the Impact of Fortetropin® on Canine Muscle Loss after Surgery, at a Major Veterinary Conference, January 20, 2019

    Results Relevant to Company's Veterinary and Human Nutrition Business CEDAR KNOLLS, N.J. , Jan. 8, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), ...

  • PR Newswire6 months ago

    MYOS RENS Technology Receives a New Patent from the United States Patent and Trademark Office

    CEDAR KNOLLS, N.J., Jan. 3, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it received the United States Patent # 10,165,785 titled, "Process for Producing Composition for Increasing Muscle Mass" from the United States Patent and Trademark Office (USPTO) on January 1, 2019.  This new patent significantly enhances MYOS' existing intellectual property portfolio, enabling MYOS to protect its advanced technologies for the development of innovative nutrition products to address musculoskeletal health.

  • PR Newswire6 months ago

    MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders

    This year has been all about leveraging Fortetropin® across our sports nutrition and veterinary nutrition verticals while solidifying our clinical research programs, and we have made great progress positioning the company to accelerate our revenue-generating efforts. With the launch of Yolked, we announced that The Vitamin Shoppe® will carry Yolked at its 775 store locations across the U.S. and online at vitaminshoppe.com later this month.

  • PR Newswire6 months ago

    MYOS RENS Technology Announces Results of Its 2018 Annual Meeting of Stockholders

    ERIC ZALTAS JOINS BOARD OF DIRECTORS CEDAR KNOLLS, N.J. , Dec. 13, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition ...

  • ACCESSWIRE6 months ago

    Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics

    NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday’s trading session. MYOS RENS shares soared after news of its product being launched with The Vitamin Shoppe. The fact that a generic version of Corcept Therapeutics’ Korlym drug may not happen for a while had traders cheering and sending the stock higher.

  • PR Newswire7 months ago

    MYOS RENS Technology Launches 'Yolked®', Its Sports Nutrition Product, With The Vitamin Shoppe® Nationwide

    CEDAR KNOLLS, N.J., Dec. 11, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that The Vitamin Shoppe® will distribute  MYOS' muscle-enhancing sports nutrition product line, 'Yolked®' formulated with Fortetropin®. The Vitamin Shoppe® will be the first retailer to carry Yolked® at its 775 store locations across the U.S. and online at vitaminshoppe.com later this month.

  • PR Newswire7 months ago

    MYOS RENS Technology Announces Approval of $1.2 Million in NJEDA NOL Program Tax Credits

    CEDAR KNOLLS, N.J., Dec. 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it has received approval from the New Jersey Economic Development Authority ("NJEDA") to transfer approximately $1.2 million in available tax benefits. "This non-dilutive funding will be used for general working capital without reducing investor value or adding debt to our balance sheet," said Joseph Mannello, Chief Executive Officer. MYOS will be able to transfer its tax benefits through the NJEDA New Jersey Technology Business Tax Certificate Transfer Program, which provides a mechanism for approved New Jersey technology and biotechnology companies to sell their unused net operating loss carryovers and research and development tax credits for cash.

  • PR Newswire7 months ago

    MYOS RENS Technology Reports Financial Results for the Third Quarter of 2018 and Business Updates

    Conference Call to be Held Thursday, November 15, 2018, at 10:30am ET CEDAR KNOLLS, N.J. , Nov. 14, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: ...

  • PR Newswire8 months ago

    MYOS RENS Technology Signs Distribution Agreement With Miller Veterinary Supply East To Bring Innovative MYOS Canine Muscle Formula™ To 6,000+ Veterinary Hospitals

    CEDAR KNOLLS, N.J., Nov. 8, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it has signed a distribution agreement with Miller Veterinary Supply East ("Miller"), which will allow MYOS to sell its MYOS Canine Muscle Formula ("MYOS Canine") in more than 6,000 Veterinary hospitals.

  • PR Newswire8 months ago

    MYOS RENS Technology Announces The Date For The Release Of Third Quarter 2018 Results, Conference Call And Webcast

    CEDAR KNOLLS, N.J., Nov. 6, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ:MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that it will provide financial results for the third quarter of 2018 on Tuesday, November 13 after the market closes. The company will host a conference call on Thursday, November 15, 2018 at 10:30 am ET, at which time MYOS Chief Executive Officer Joseph Mannello will provide commentary on earnings results for the third quarter and provide an update on the business.

  • PR Newswire9 months ago

    Centers For Medicare and Medicaid Services Approves Reimbursement For Unique Fortetropin®-Based Enteral Nutrition Formula

    CEDAR KNOLLS, N.J., Oct. 2, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that MYOS Enteral Nutrition Formula, formulated with Fortetropin®, has become eligible for Medicare and Medicaid reimbursement. Specifically, the formula has been approved as an HCPCS B4150 Product after review by the Pricing, Data Analysis, and Coding Contractor for the Centers for Medicare and Medicaid Services ("CMS").  This HCPCS B4150 code is used to describe enteral formulas which are nutritionally complete with intact nutrients, including proteins, fats, carbohydrates, vitamins, and minerals.